Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q2

4671.TEDINET S100S7JG
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥21.3bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥46.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥24.2bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥851m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥1.7bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥931m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.9bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥1.1bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥1.9bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥629m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥629m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥36.7bnat 2023-09-30Cons.Assets
Total assets¥38.9bnat 2023-03-31Cons.Assets
Total assets¥38.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥10.7bnat 2023-09-30Cons.Liabilities
Total liabilities¥12.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥26.0bnat 2023-09-30Cons.Net assets
Net assets / equity¥26.6bnat 2023-03-31Cons.Net assets
Net assets / equity¥24.3bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥9.2bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥12.6bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥9.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.6bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥10.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥322m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥249m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥448m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥937m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥56.292023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥45.342023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥215.292022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥107.52022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥65.162022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥56.142023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥214.032022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥107.182022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio70.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio68.2%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥270m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥689m
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥385m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥46m
—segment totalrevenue2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥0
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥213m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥15.9bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥15.9bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.7bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥320m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥293m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥293m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥99m
—segment totalrevenue2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥4m
—segment totalsegment profit2022-04-01 → 2022-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 539
ItemContextValueUnit
Short term loans payablePrior1YearInstant－JPY
Short term loans payableCurrentQuarterInstant500000000JPY
Current portion of long term loans payablePrior1YearInstant2340000000JPY
Current portion of long term loans payableCurrentQuarterInstant－JPY
Income taxes payablePrior1YearInstant181000000JPY
Income taxes payableCurrentQuarterInstant440000000JPY
Provision for bonusesPrior1YearInstant557000000JPY
Provision for bonusesCurrentQuarterInstant541000000JPY
Other clPrior1YearInstant2111000000JPY
Other clCurrentQuarterInstant2153000000JPY
Current liabilitiesPrior1YearInstant9564000000JPY
Current liabilitiesCurrentQuarterInstant8128000000JPY
Net defined benefit liabilityPrior1YearInstant1849000000JPY
Net defined benefit liabilityCurrentQuarterInstant1812000000JPY
Asset retirement obligations nclPrior1YearInstant134000000JPY
Asset retirement obligations nclCurrentQuarterInstant61000000JPY
Other nclPrior1YearInstant752000000JPY
Other nclCurrentQuarterInstant711000000JPY
Noncurrent liabilitiesPrior1YearInstant2736000000JPY
Noncurrent liabilitiesCurrentQuarterInstant2585000000JPY
LiabilitiesPrior1YearInstant12301000000JPY
LiabilitiesCurrentQuarterInstant10714000000JPY
Capital stockPrior1YearInstant3371000000JPY
Capital stockCurrentQuarterInstant3371000000JPY
Capital surplusPrior1YearInstant3670000000JPY
Capital surplusCurrentQuarterInstant3669000000JPY
Retained earningsPrior1YearInstant19025000000JPY
Retained earningsCurrentQuarterInstant18892000000JPY
Treasury stockPrior1YearInstant-94000000JPY
Treasury stockCurrentQuarterInstant-513000000JPY
Shareholders equityPrior1YearInstant25973000000JPY
Shareholders equityCurrentQuarterInstant25419000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant535000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant533000000JPY
Valuation and translation adjustmentsPrior1YearInstant535000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant533000000JPY
Subscription rights to sharesPrior1YearInstant82000000JPY
Subscription rights to sharesCurrentQuarterInstant78000000JPY
Net assetsPrior1YearInstant26591000000JPY
Net assetsCurrentQuarterInstant26032000000JPY
Liabilities and net assetsPrior1YearInstant38893000000JPY
Liabilities and net assetsCurrentQuarterInstant36746000000JPY
Net salesPrior1YTDDuration24151000000JPY
Net salesCurrentYTDDuration21325000000JPY
Cost of salesPrior1YTDDuration16490000000JPY
Cost of salesCurrentYTDDuration14884000000JPY
Gross profitPrior1YTDDuration7661000000JPY
Gross profitCurrentYTDDuration6440000000JPY
Selling general and administrative expensesPrior1YTDDuration5920000000JPY
Selling general and administrative expensesCurrentYTDDuration5589000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass